EP PerMed is a new European Partnership dedicated to Personalised Medicine (PM). It supports PM-related R&I, but also facilitates and accelerates all steps so that PM achievements successfully pass through the full value continuum to be implemented in sustainable health systems for the benefit of people and societies. The partnership will foster demonstration projects and promote successes and lessons learned to demonstrate evidence of PM implementation. EP PerMed activities cover overarching aspects, like patient involvement, exchange with medical societies, infrastructures and international and regional collaboration. The project portfolios of EP PerMed and ERA PerMed (ERA-Net co-fund on PM) and others are supported to become successful innovations in healthcare practice. EP PerMed will be the global PM-platform for scientific and strategic dialogue and alignment, resulting in public documents and publications. Accordingly, it will inform the public, patients, healthcare providers or payers about the latest PM options and engage them. The Strategic Research and Innovation Agenda for Personalised Medicine (SRIA for PM, 2023), developed by EP PerMed partners, is the basis for the partnership's structure and a wide range of its activities. All steps of the SRIA development were strongly support by numerous PM-experts, stakeholders and the European Commission (EC). Thus, the EP PerMed annual Joint Transnational Calls (JTCs) and other funding and activities, events and tools will be in line with the SRIA and outputs will feed into a SRIA update in the coming years. The partnership builds on several developments, initiatives and projects such as ERA PerMed, ICPerMed and its supporting projects (“ICPerMed Family”) funded by the EC. In parallel, it reaches out to the 1+Million Genomes Initiative, other European Partnerships in the Health Cluster and infrastructures like the European Strategy Forum on Research Infrastructures (ESFRI).

ERA PerMed will serve as a funding vehicle of topics identified in the Strategic Research and Innovation Agenda (SRIA) in Personalised Medicine and the Action Plan of ICPerMed. ERA PerMed will coordinate R&I efforts of the participating partners (funding agencies from EU, associate countries to H2020 and third countries). The main objective is planning, implementing, monitoring and disseminate up to four joint transnational calls (JTCs) tackling the value change in full to fund multidisciplinary transnational research projects covering each at least three slots of the value chain regarding Personalised Medicine. The ERA PerMed consortium is open to enlargement for the planned JTCs. According to funding scheme’s rules, ERA PerMed partners commit themselves to implement one call with top-up co-funding from the EC, and include funded project monitoring. Additionally, up to three non-cofunded calls will be carried, in order to broaden the scope of action of the efforts made by the EC and funding organizations to foster the Personalised Medicine Research Community and to be able to take into account recent changes within the landscape of personalised medicine, e.g. new developments of emerging technologies and societal challenges, which reinforces and amplifies the expected impact of ERA PerMed funding activity. Cooperation and links with ICPerMed and a dialogue with patient organisations, other European stakeholders and initiatives are crucial for both R&I and the implementation of their results and sustainability, which reinforces and amplifies the expected impact of ERA PerMed funding activity.